Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1974 2
1976 2
1977 2
1980 1
1981 2
1982 2
1983 2
1985 1
1986 1
1987 1
1988 5
1989 1
1990 1
1991 4
1992 2
1994 3
1995 8
1997 4
1998 3
1999 5
2000 1
2001 1
2002 2
2003 3
2005 3
2006 3
2008 3
2009 5
2010 5
2011 6
2012 6
2013 2
2014 4
2015 4
2016 4
2017 3
2018 8
2019 8
2020 5
2021 9
2022 13
2023 10
2024 13
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML; ASPEN Investigators. Chalmers JD, et al. N Engl J Med. 2025 Apr 24;392(16):1569-1581. doi: 10.1056/NEJMoa2411664. N Engl J Med. 2025. PMID: 40267423 Clinical Trial.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Middleton PG, et al. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. N Engl J Med. 2019. PMID: 31697873 Free PMC article. Clinical Trial.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection.
Foo CX, Bartlett S, Chew KY, Ngo MD, Bielefeldt-Ohmann H, Arachchige BJ, Matthews B, Reed S, Wang R, Smith C, Sweet MJ, Burr L, Bisht K, Shatunova S, Sinclair JE, Parry R, Yang Y, Lévesque JP, Khromykh A, Rosenkilde MM, Short KR, Ronacher K. Foo CX, et al. Among authors: burr l. Eur Respir J. 2023 Mar 9;61(3):2201306. doi: 10.1183/13993003.01306-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36396144 Free PMC article.
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A; VX20-121-102 Study Group; VX20-121-103 Study Group. Keating C, et al. Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2. Lancet Respir Med. 2025. PMID: 39756424 Free PMC article. Clinical Trial.
Microfabricated self-referencing pulstrodes.
Speck A, Migliorelli D, Disser J, Generelli S, Bouilly G, Forrest T, Zdrachek E, Burr L, Bakker E. Speck A, et al. Among authors: burr l. Sens Diagn. 2025 May 14;4(8):669-679. doi: 10.1039/d5sd00024f. eCollection 2025 Aug 7. Sens Diagn. 2025. PMID: 40476077 Free PMC article.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.
Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis.
Sajiir H, Keshvari S, Wong KY, Borg DJ, Steyn FJ, Fercher C, Taylor K, Taylor B, Barnard RT, Müller A, Moniruzzaman M, Miller G, Wang R, Fotheringham A, Schreiber V, Sheng YH, Hancock JL, Loo D, Burr L, Huynh T, Lockett J, Ramm GA, Macdonald GA, Prins JB, McGuckin MA, Hasnain SZ. Sajiir H, et al. Among authors: burr l. Nat Commun. 2024 May 29;15(1):4528. doi: 10.1038/s41467-024-48317-x. Nat Commun. 2024. PMID: 38811532 Free PMC article.
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study.
Sibila O, Stobo J, Perea L, Gao YH, Xu JF, Lind H, Viligorska K, Spinou A, Polverino E, Ringshausen FC, Vendrell M, Burgel PR, Haworth CS, Loebinger MR, Lorent N, Dhar R, Choi H, Chotirmall SH, De Soyza A, Hurst JR, Brown JS, van der Eerden M, Kauppi P, Johnson ED, Mendez R, Dimakou K, Bossios A, Torres A, Blasi F, Shteinberg M, Elborn SJ, Goeminne PC, Aliberti S, Jayaram L, Karalus N, Taylor SL, Martin ML, Burr LD, Wong C, Terpstra L, Altenburg J, Boersma W, Chalmers JD. Sibila O, et al. Among authors: burr ld. Lancet Respir Med. 2025 Oct;13(10):911-920. doi: 10.1016/S2213-2600(25)00160-2. Epub 2025 Aug 27. Lancet Respir Med. 2025. PMID: 40885209 Free article.
Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function.
Sinclair JE, Vedelago C, Ryan FJ, Carney M, Redd MA, Lynn MA, Grubor-Bauk B, Cao Y, Henders AK, Chew KY, Gilroy D, Greaves K, Labzin L, Ziser L, Ronacher K, Wallace LM, Zhang Y, Macauslane K, Ellis DJ, Rao S, Burr L, Bain A, Karawita A, Schulz BL, Li J, Lynn DJ, Palpant N, Wuethrich A, Trau M, Short KR. Sinclair JE, et al. Among authors: burr l. Nat Microbiol. 2024 Dec;9(12):3135-3147. doi: 10.1038/s41564-024-01838-z. Epub 2024 Oct 30. Nat Microbiol. 2024. PMID: 39478108 Free PMC article.
170 results